Company Overview and News

 
Top 6 Cobalt Junior Developer Miners To Boom By 2021/2022

2018-05-17 seekingalpha
Six cobalt junior developers can each produce ~5,000 tonnes pa of cobalt by 2021/22. These companies each have the potential to be worth ~AUD 3b if cobalt prices remain strong.

1
Cobalt Miners News For The Month Of April 2018

2018-04-25 seekingalpha
Cobalt miner news - South Korea's LG Chem to set up battery material JVs with China's Zhejiang Huayou Cobalt.

1
A Look At The Junior Cobalt Miners In Early 2018

2018-04-17 seekingalpha
This article first appeared on Trend Investing on February 16, therefore all data is as of that date.

 
Aeon Metals fancied by Bell Potter with imminent news flow and prospect of production in 2020

2018-03-26 proactiveinvestors.com.au
Aeon Metals Ltd (ASX:AML) has caught the attention of Bell Potter with the broker maintaining its buy recommendation and upgrading its price target from 48 cents to 50 cents.

1
Cobalt Miners News For The Month Of March 2018

2018-03-25 seekingalpha
Cobalt spot price news - Spot prices rise 18.7% in the past month as inventory falls. The cobalt spot price is now over USD 40/lb, and approaching USD 100,000/tonne.

 
Australia Mines Offers Nickel-Cobalt Exposure With Three Promising Projects In Australia

2018-03-21 seekingalpha
The Sconi resource estimate has 54,500 tonnes of contained cobalt with exploration upside. The Sconi project has recently secured 100% cobalt and nickel off-take.

1
Time To Buy Some Cobalt Miners

2018-03-09 seekingalpha
The cobalt miners strangely fell in January following the lithium miners despite very strong cobalt price gains.

4
Cobalt Miners News For The Month Of February 2018

2018-02-23 seekingalpha
Cobalt market news - the DRC to hike taxes on Congo cobalt miners. ERG says "cobalt boom ‘guaranteed’ for 7-10 years."

6
Cobalt Miners News For The Month Of January 2018

2018-01-24 seekingalpha
Cobalt spot price news - Cobalt prices up again in January. "BMO Capital Markets expects current cobalt prices to double in the next two years."

1
Traka Resources exercises option over Gorge Creek cobalt prospect

2018-01-05 proactiveinvestors.com.au
Traka Resources Ltd (ASX:TKL) has exercised its option to the polymetallic Gorge Creek Project located to the northern extent of the Queensland Northern Territory border.

2
Cobalt Miners News For The Month Of December 2017

2017-12-22 seekingalpha
Cobalt market news - "Electric vehicle revolution a rare investment opportunity as metals demand spikes." "BMW sees 10-fold jump in its need for battery materials by 2025."

 
Australia cobalt rush accelerates on electric vehicle demand, DRC troubles

2017-12-15 reuters
MELBOURNE (Reuters) - Australia, home to the world’s second-biggest cobalt reserves, is seeing a rush of interest in projects still years from production as makers of batteries used in electric vehicles (EVs) seek supplies of the metal from a more costly but less risky source than top miner, the Democratic Republic of Congo.

 
Aeon Metals attracts $30 million for one of Australia’s biggest undeveloped copper cobalt projects

2017-12-15 proactiveinvestors.com.au
Aeon Metals Ltd (ASX:AML) is raising $30 million via a significantly oversubscribed institutional share placement to new and existing investors, at $0.28 per share.

 
Traka Resources leverages itself to highly prospective Mt Isa Inlier and Carpentaria Province

2017-11-26 proactiveinvestors.com.au
Traka Resources Ltd (ASX:TKL) recently reached an agreement with a private company, Cobalt QLD Pty Ltd, on the Gorge Creek Project.

1
Cobalt Miners News For The Month Of October 2017

2017-10-24 seekingalpha
Cobalt market news - Auto manufacturers have turned their focus to the raw materials needed to feed the EV boom.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...